AWS
RXRX icon

Atria Wealth Solutions’s Recursion Pharmaceuticals RXRX Stock Holding History

Atria Wealth Solutions’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-11,123
Closed -$75.2K – 2052
2024
Q4 		$75.2K Buy
+11,123
New +$74.8K ﹤0.01% 1919

Other funds holding RXRX

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
KA
Kinnevik AB Stockholm, Sweden $65.6M AUM 25.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
MIC
Mubadala Investment Company Abu Dhabi, United Arab Emirates $34.8B AUM 107.63% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return

Atria Wealth Solutions's RXRX Position: Q1 2025 in Review

Atria Wealth Solutions sold out of Recursion Pharmaceuticals (RXRX) in Q1 2025, closing a stake of 11,123 shares — an estimated $75.2K sold.

Atria Wealth Solutions first reported a position in RXRX in Q4 2024 and held it in 1 quarter. The position peaked at $75.2K in Q4 2024. 336 funds tracked by Wall St. Rank hold RXRX as of Q1 2025.

  • Atria Wealth Solutions reported no remaining Recursion Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Atria Wealth Solutions sold 11,123 Recursion Pharmaceuticals shares in Q1 2025, an estimated $75.2K.
  • Atria Wealth Solutions first reported a position in Recursion Pharmaceuticals in Q4 2024 and held it in 1 quarter.
  • Atria Wealth Solutions's Recursion Pharmaceuticals position peaked at $75.2K in Q4 2024.
  • 336 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2025.

Based on Atria Wealth Solutions's 13F filing for Q1 2025, filed 9 May 2025.